PHI News Room
All News and Press Releases
Enter any phrase or word you would like to search for and click .
PostNews: Press Release
Founder and board member subscribes for shares in the ongoing rights issue
Peter Egelberg, founder and Board member of Phase Holographic Imaging PHI AB has notified the Company that he, together with closely related parties, follows Altium SA’s lead by subscribing for shares in the Company’s ongoing fully secured rights issue. The subscription amounts to approximately 300 TSEK.
PostNews: Press Release
PHI at Aktieportföljen Live, BioStock and Financial Stockholm
The subscription period in PHI AB’s fully secured rights issue, totalling SEK 64.3 million, is ongoing until 20 December 2024. The Company’s CEO, Anders Månsson, has during the last couple of weeks presented the Company and its future plans. For links to the presentations and the podcast, see below.
PostNews: Press Release
Notice of Annual General Meeting in Phase Holographic Imaging PHI AB (publ) 8 January 2025
The shareholders of Phase Holographic Imaging PHI AB (publ), (“the Company”), reg.no. 556542-7811, are hereby invited to attend the general meeting on 8 January 2025 at 15.00 at the Company´s office at Skiffervägen 48 in Lund.
PostNews: Press Release
The subscription period in PHI’s fully secured rights issue commences today
PostNews: Press Release
PHI publishes prospectus due to upcoming rights issue
PostNews
BioStock: Studio interview with Anders Månsson and Goran Dubravčić
Recently, PHI welcomed Anders Månsson as its new CEO. In a video interview, Månsson and Chairman of the Board Goran Dubravčić discuss the company’s future strategy and the ongoing rights issue.
Company News
Here, you see PHI featured in recent news and find previous CEO commentaries.
BioStock: PHI aims for US listing
BioStock has talked to PHI’s CEO, Patrik Eschricht, to learn more about what the dual listing on the US OTCQB market means for the company and its plans for the future.
BioStock: PHI grows its network of collaborations
BioStock caught up with PHI’s CEO Patrik Eschricht to ask about his outlook for the growing number of academic collaborations and sales partnerships.
BioStock: PHI “It’s the right moment to capitalize on regenerative medicine momentum.”
BioStock contacted CEO Patrik Eschricht for an update on the company’s progress and how PHI will capitalize on the current momentum.
BioStock: Shift to regenerative medicine increases growth prospects for PHI
BioStock talked to our CEO, Patrik Eschricht, for an operational overview and to learn about the current behind-the-scenes developments, as PHI has a growth trajectory that is on a notable upward trend, marked by its highest-ever sales performances in the last quarter.
